Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04863872 · ClinicalTrials.gov registry record · NA
Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2)
A NA study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- NA
- Development phase
- 259
- Enrollment target
NCT04863872: Completed NA study, sponsored by Kaiser Permanente.
NCT04863872 is a NA study that has completed, run by Kaiser Permanente. The registered enrollment target is 259 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04863872, a NA study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- NA
- Development phase
- 259 participants
- Enrollment target
Study Summary
Severe hypoglycemia is the most feared complication of medications used to lower blood glucose levels in patients with diabetes. Severe hypoglycemia, defined as plasma glucose low enough to require assistance, has been linked to poor health-related quality of life, emotional and interpersonal challenges, car accidents, serious falls, cardiovascular events, dementia, and death. Older adults with type 2 diabetes are particularly vulnerable to the complications of severe hypoglycemia. Each year, approximately 11% of patients with type 2 diabetes self-report severe hypoglycemia episodes. An estimated 14% of emergency hospitalizations of older Americans for adverse drug events implicate insulin and 11% implicate oral hypoglycemic agents. One in four diabetes-related hospital admissions is for hypoglycemia. This study will compare two ways to reduce severe hypoglycemia in people with type 2 diabetes. The two methods to be compared are: 1. Proactive care management. This will be a nurse outreach call which is similar to the usual care that people with type 2 diabetes get to reduce their risk of severe hypoglycemia, but given in advance rather than in response to a recent severe hypoglycemia event. 2. The same proactive care management (nurse outreach call) plus enrollment in MyHC-T2D, a health education program aimed at improving awareness of hypoglycemia and preventing severe hypoglycemia. This program has been shown to reduce severe hypoglycemia in people with type 1 diabetes but has not been tested in persons with type 2. Our hypothesis is that proactive care management plus MyHC-T2D will be more effective than proactive care management alone at preventing self-reported severe hypoglycemia in adults with type 2 diabetes at high risk for severe hypoglycemia. The primary outcome will be measured using surveys at the beginning of the study and 14-months later.
Primary Outcome
Any self-reported severe hypoglycemia in prior 12 months
Interventions
- OTHER Proactive Care Management
- BEHAVIORAL MyHC-T2D education program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2022-01-26 |
| Est. Completion | 2024-06-21 |
| Phase | NA |
What the finished NCT04863872 record still lists
NCT04863872 is an interventional study that assigns participants to a tested intervention. The registered 259 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Proactive Care Management is the first listed.
NCT04863872 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04863872 about?
NCT04863872 is a clinical study titled "Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2)". Severe hypoglycemia is the most feared complication of medications used to lower blood glucose levels in patients with diabetes. Severe hypoglycemia, defined as plasma glucose low enough to require assistance, has been linked to poor health-related quality of life, emotional and interpersonal challe...
What is the current status of trial NCT04863872?
This trial is currently completed. It is a NA study. The enrollment target is 259 participants. The study started on 2022-01-26. Estimated completion is 2024-06-21.
What interventions are being tested in trial NCT04863872?
The interventions under investigation include: Proactive Care Management (OTHER), MyHC-T2D education program (BEHAVIORAL).
Who is sponsoring clinical trial NCT04863872?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04863872's enrollment target sits among peer trials
259 400th of 2000 higher than 1,599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02361320 · 259 participants · NA
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
- NCT06797258 · 259 participants · NA
FlexHD® Pliable Investigation in Implant-Based Breast Reconstruction
- NCT06990425 · 259 participants · NA
CLOSM Trial: Groin Closure Using Layered Option for Suture Material
- NCT07399977 · 259 participants · NA
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI